WINTON GROUP Ltd Increases Stake in STAAR Surgical (NASDAQ:STAA)

WINTON GROUP Ltd grew its holdings in shares of STAAR Surgical (NASDAQ:STAA) by 41.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 42,964 shares of the medical instruments supplier’s stock after purchasing an additional 12,496 shares during the quarter. WINTON GROUP Ltd owned approximately 0.09% of STAAR Surgical worth $1,044,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. Quarry LP acquired a new position in STAAR Surgical during the third quarter worth about $50,000. Quest Partners LLC purchased a new position in STAAR Surgical in the 3rd quarter worth approximately $128,000. KLP Kapitalforvaltning AS acquired a new position in shares of STAAR Surgical during the 4th quarter worth approximately $180,000. FMR LLC grew its position in shares of STAAR Surgical by 79.3% in the third quarter. FMR LLC now owns 7,092 shares of the medical instruments supplier’s stock valued at $263,000 after purchasing an additional 3,136 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of STAAR Surgical in the fourth quarter valued at approximately $278,000. Hedge funds and other institutional investors own 96.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Canaccord Genuity Group cut their target price on STAAR Surgical from $28.00 to $17.00 and set a “hold” rating for the company in a research note on Thursday, February 13th. Stephens restated an “equal weight” rating and set a $17.00 price objective on shares of STAAR Surgical in a research report on Tuesday, March 18th. Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a report on Thursday, February 27th. StockNews.com downgraded shares of STAAR Surgical from a “hold” rating to a “sell” rating in a report on Thursday, February 13th. Finally, Stifel Nicolaus decreased their price objective on STAAR Surgical from $38.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday, February 12th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $25.29.

STAAR Surgical Price Performance

STAA opened at $17.79 on Friday. The business has a fifty day moving average price of $19.43 and a 200 day moving average price of $25.23. STAAR Surgical has a 12 month low of $13.50 and a 12 month high of $52.68. The stock has a market capitalization of $877.49 million, a price-to-earnings ratio of -43.39 and a beta of 0.66.

Insider Buying and Selling

In other news, major shareholder Broadwood Partners, L.P. bought 3,620 shares of the stock in a transaction that occurred on Thursday, March 27th. The stock was purchased at an average price of $17.48 per share, for a total transaction of $63,277.60. Following the completion of the purchase, the insider now owns 12,424,944 shares in the company, valued at approximately $217,188,021.12. This trade represents a 0.03 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last ninety days, insiders have bought 1,074,103 shares of company stock worth $17,900,948. Company insiders own 1.00% of the company’s stock.

STAAR Surgical Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.